title: In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012-2014.
abstract: The objective of this report was to document antimicrobial susceptibility testing surveillance data for ceftaroline and comparative agents from the AWARE (Assessing Worldwide Antimicrobial Resistance Evaluation) global surveillance program for bacterial pathogens causing skin and soft tissue and respiratory tract infections in African and Middle Eastern countries from 2012 through 2014. Pathogen identities were confirmed by MALDI-TOF and antimicrobial susceptibility testing performed by CLSI broth microdilution methodology in a central laboratory. All methicillin-susceptible Staphylococcus aureus (MSSA) (n= 923; MIC90, 0.25 μg/mL) and 91.8% of methicillin-resistant S. aureus (MRSA) (n= 1161; MIC90, 1 μg/mL) tested were susceptible to ceftaroline. The maximum ceftaroline MIC observed for isolates of MRSA was 2 μg/mL. All Streptococcus pyogenes (n= 174; MIC90, 0.008 μg/mL), Streptococcus agalactiae (n= 44; MIC90, 0.015 μg/mL), Streptococcus pneumoniae (n= 351; MIC90, 0.25 μg/mL), and Haemophilus influenzae (n= 84; MIC90, ≤0.015 μg/mL) were susceptible to ceftaroline. Rates of susceptibility to ceftaroline among ESBL-negative Escherichia coli (n= 338), Klebsiella pneumoniae (n= 241), and Klebsiella oxytoca (n= 97) were 89.1% (MIC90, 1 μg/mL), 94.2% (MIC90, 0.5 μg/mL), and 99.0% (MIC90, 0.5 μg/mL), respectively.
authors.affiliation: International Health Management Associates, Inc., Schaumburg, IL, USA.
authors.forename: James A
authors.initials: JA
authors.lastname: Karlowsky
authors.affiliation: International Health Management Associates, Inc., Schaumburg, IL, USA. Electronic address: dbiedenbach@ihmainc.com.
authors.forename: Douglas J
authors.initials: DJ
authors.lastname: Biedenbach
authors.affiliation: International Health Management Associates, Inc., Schaumburg, IL, USA.
authors.forename: Samuel K
authors.initials: SK
authors.lastname: Bouchillon
authors.affiliation: International Health Management Associates, Inc., Schaumburg, IL, USA.
authors.forename: Meredith
authors.initials: M
authors.lastname: Hackel
authors.affiliation: AstraZeneca Pharmaceuticals, Waltham, MA, USA.
authors.forename: Joseph P
authors.initials: JP
authors.lastname: Iaconis
authors.affiliation: International Health Management Associates, Inc., Schaumburg, IL, USA.
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Sahm
mesh_terms: D000349:Africa / Q000453:epidemiology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification*; D002511:Cephalosporins / Q000494:pharmacology*; D062665:Epidemiological Monitoring; D006801:Humans; D008826:Microbial Sensitivity Tests; D008877:Middle East / Q000453:epidemiology; D012141:Respiratory Tract Infections / Q000453:epidemiology / Q000382:microbiology*; D017192:Skin Diseases, Bacterial / Q000453:epidemiology / Q000382:microbiology*; D018461:Soft Tissue Infections / Q000453:epidemiology / Q000382:microbiology*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D000097583:Ceftaroline
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000097583:Ceftaroline
keywords: AWARE; Africa; Ceftaroline; MRSA; Middle East; Surveillance